Huntington disease reduced penetrance alleles occur at high frequency in the general population

被引:64
作者
Kay, Chris [1 ]
Collins, Jennifer A. [1 ]
Miedzybrodzka, Zosia [2 ]
Madore, Steven J. [3 ]
Gordon, Erynn S. [3 ]
Gerry, Norman [3 ]
Davidson, Mark [2 ]
Slama, Ramy A. [1 ]
Hayden, Michael R. [1 ]
机构
[1] Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 1M9, Canada
[2] Univ Aberdeen, Sch Med & Dent, Med Genet Grp, Aberdeen AB9 1FX, Scotland
[3] Coriell Inst Med Res, Mol Biol Grp, Camden, NJ USA
基金
加拿大健康研究院;
关键词
AGE-OF-ONSET; HD; INSTABILITY; HAPLOTYPES; PREDICTION; MUTATION; UTILITY;
D O I
10.1212/WNL.0000000000002858
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To directly estimate the frequency and penetrance of CAG repeat alleles associated with Huntington disease (HD) in the general population. Methods: CAG repeat length was evaluated in 7,315 individuals from 3 population-based cohorts from British Columbia, the United States, and Scotland. The frequency of >= 36 CAG alleles was assessed out of a total of 14,630 alleles. The general population frequency of reduced penetrance alleles (36-39 CAG) was compared to the prevalence of patients with HD with genetically confirmed 36-39 CAG from a multisource clinical ascertainment in British Columbia, Canada. The penetrance of 36-38 CAG repeat alleles for HD was estimated for individuals >= 65 years of age and compared against previously reported clinical penetrance estimates. Results: A total of 18 of 7,315 individuals had >= 36 CAG, revealing that approximately 1 in 400 individuals from the general population have an expanded CAG repeat associated with HD (0.246%). Individuals with CAG 36-37 genotypes are the most common (36, 0.096%; 37, 0.082%; 38, 0.027%; 39, 0.000%; >= 40, 0.041%). General population CAG 36-38 penetrance rates are lower than penetrance rates extrapolated from clinical cohorts. Conclusion: HD alleles with a CAG repeat length of 36-38 occur at high frequency in the general population. The infrequent diagnosis of HD at this CAG length is likely due to low penetrance. Another important contributing factor may be reduced ascertainment of HD in those of older age.
引用
收藏
页码:282 / 288
页数:7
相关论文
共 32 条
  • [1] A global reference for human genetic variation
    Altshuler, David M.
    Durbin, Richard M.
    Abecasis, Goncalo R.
    Bentley, David R.
    Chakravarti, Aravinda
    Clark, Andrew G.
    Donnelly, Peter
    Eichler, Evan E.
    Flicek, Paul
    Gabriel, Stacey B.
    Gibbs, Richard A.
    Green, Eric D.
    Hurles, Matthew E.
    Knoppers, Bartha M.
    Korbel, Jan O.
    Lander, Eric S.
    Lee, Charles
    Lehrach, Hans
    Mardis, Elaine R.
    Marth, Gabor T.
    McVean, Gil A.
    Nickerson, Deborah A.
    Wang, Jun
    Wilson, Richard K.
    Boerwinkle, Eric
    Doddapaneni, Harsha
    Han, Yi
    Korchina, Viktoriya
    Kovar, Christie
    Lee, Sandra
    Muzny, Donna
    Reid, Jeffrey G.
    Zhu, Yiming
    Chang, Yuqi
    Feng, Qiang
    Fang, Xiaodong
    Guo, Xiaosen
    Jian, Min
    Jiang, Hui
    Jin, Xin
    Lan, Tianming
    Li, Guoqing
    Li, Jingxiang
    Li, Yingrui
    Liu, Shengmao
    Liu, Xiao
    Lu, Yao
    Ma, Xuedi
    Tang, Meifang
    Wang, Bo
    [J]. NATURE, 2015, 526 (7571) : 68 - +
  • [2] Huntington disease
    Bates, Gillian P.
    Dorsey, Ray
    Gusella, James F.
    Hayden, Michael R.
    Kay, Chris
    Leavitt, Blair R.
    Nance, Martha
    Ross, Christopher A.
    Scahill, Rachael I.
    Wetzel, Ronald
    Wild, Edward J.
    Tabrizi, Sarah J.
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2015, 1
  • [3] Bean Lora, 2014, Genet Med, V16, pe2, DOI 10.1038/gim.2014.146
  • [4] Characterization of a Large Group of Individuals with Huntington Disease and Their Relatives Enrolled in the COHORT Study
    Dorsey, E. Ray
    [J]. PLOS ONE, 2012, 7 (02):
  • [5] Measurement of mutational flow implies both a high new-mutation rate for Huntington disease and substantial underascertainment of late-onset cases
    Falush, D
    Almqvist, EW
    Brinkmann, RR
    Iwasa, Y
    Hayden, MR
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (02) : 373 - 385
  • [6] Multisource Ascertainment of Huntington Disease in Canada: Prevalence and Population at Risk
    Fisher, Emily R.
    Hayden, Michael R.
    [J]. MOVEMENT DISORDERS, 2014, 29 (01) : 105 - 114
  • [7] LATE-ONSET HUNTINGTONS-DISEASE - A CLINICAL AND MOLECULAR STUDY
    JAMES, CM
    HOULIHAN, GD
    SNELL, RG
    CHEADLE, JP
    HARPER, PS
    [J]. AGE AND AGEING, 1994, 23 (06) : 445 - 448
  • [8] Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry
    Kay, Chris
    Collins, Jennifer A.
    Skotte, Niels H.
    Southwell, Amber L.
    Warby, Simon C.
    Caron, Nicholas S.
    Doty, Crystal N.
    Nguyen, Betty
    Griguoli, Annamaria
    Ross, Colin J.
    Squitieri, Ferdinando
    Hayden, Michael R.
    [J]. MOLECULAR THERAPY, 2015, 23 (11) : 1759 - 1771
  • [9] Keller MA, 2010, PERS MED, V7, P301, DOI [10.2217/pme.10.13, 10.2217/PME.10.13]
  • [10] KREMER B, 1994, NEW ENGL J MED, V330, P1401, DOI [DOI 10.1056/NEJM199405193302001, 10.1056/nejm199405193302001]